Social determinants of health are being carefully tended to in the Medicare populations, explained Lee Newcomer, MD, MHA, private consultant.
Social determinants of health are being carefully tended to in the Medicare populations, explained Lee Newcomer, MD, MHA, private consultant.
Transcript
Do payer strategies include using social and behavioral determinants of health (SBDH) in population health management?
Well here I’m speaking broadly, but yes, they do make a difference. I think where you see social determinants being really carefully tended to is in the Medicaid populations. Almost every payer in the Medicaid space is helping to provide transportation or maybe even childcare—sometimes even as far as housing because it’s clear that those issues have to be addressed if the healthcare is going to be addressed.
There are models out in the United States across the entire country where people are trying to add social determinants to make the healthcare better.
Can value-based models incentivize consideration of social and behavioral determinants of health?
I think they actually can, but again the ultimate objective is 'how do I get my patient healthy, and how can I do it for the least amount of money.' So, if social determinants help then they will be addressed. But if they aren’t going to make a difference, then they probably won’t be addressed. That’s why I come back to the Medicaid population—I think that’s the group that’s gotten, by far in a way, the best benefit from working on social determinants.
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More